Copyright 2024
| PMID | Allele | Disease | Population | Drug Names | SNP | Class | Sentence |
|---|---|---|---|---|---|---|---|
| 21739420 | HLA-DRB1 (HLA-DRB1) | rs6457620 | Tibetan | rs9275295 | rs7745040 | unclassified | |
| NA | |||||||
| 21739420 | HLA-DRB1 (HLA-DRB1) | rs6457620 | Tibetan | rs9275295 | rs7745040 | only_studied | |
| NA | |||||||
| 27819553 | HLA (HLA) | anaphylactic reaction | NA | tranexamic | NA | negation | |
| anaphylactic reaction to vwf preparations may be related to pt-vwd and the development of hla antibodies is not uncommon. | |||||||
| 23114775 | HLA (HLA) | soft tissue infection | NA | NA | NA | lack_of_evidence | |
| in murine models of skin and soft tissue infection, topical gra treatment significantly reduced skin lesion size and decreased the expression of saer and hla genes. | |||||||
| 30718654 | HLA (HLA) | soft tissue infection | NA | NA | NA | unclassified | |
| sex bias in innate defense against staphylococcus aureus skin and soft tissue infection (ssti) is dependent on both estrogen production by the host and s. aureus secretion of the virulence factor, a-hemolysin (hla). | |||||||
| 21851420 | HUMAN LEUKOCYTE ANTIGEN (HUMAN LEUKOCYTE ANTIGEN) | polycystic ovarian syndrome | Korean | testosterone | NA | unclassified | |
| association of polycystic ovarian syndrome with human leukocyte antigen polymorphism in korean women. | |||||||
| 21853121 | HLA-CLASS II (HLA CLASS II) | NA | Chinese | rs10947262 | rs7775228 | unclassified | |
| NA | |||||||
| 21975206 | HLA-DRB1*04 | secondary progressive multiple sclerosis | NA | NA | NA | unclassified | |
| a phase iii study evaluating the efficacy and safety of mbp8298 in secondary progressive ms. to evaluate the efficacy and safety of mbp8298 in subjects with secondary progressive multiple sclerosis (spms) who express human leukocyte antigen (hla) haplotype dr2 or dr4 (dr2(+) or dr4(+)). | |||||||
| 21975206 | HLA-DR2 (BROAD ANTIGEN) | secondary progressive multiple sclerosis | NA | NA | NA | unclassified | |
| a phase iii study evaluating the efficacy and safety of mbp8298 in secondary progressive ms. to evaluate the efficacy and safety of mbp8298 in subjects with secondary progressive multiple sclerosis (spms) who express human leukocyte antigen (hla) haplotype dr2 or dr4 (dr2(+) or dr4(+)). | |||||||
| 21975206 | HUMAN LEUKOCYTE ANTIGEN (HUMAN LEUKOCYTE ANTIGEN) | secondary progressive multiple sclerosis | NA | NA | NA | unclassified | |
| a phase iii study evaluating the efficacy and safety of mbp8298 in secondary progressive ms. to evaluate the efficacy and safety of mbp8298 in subjects with secondary progressive multiple sclerosis (spms) who express human leukocyte antigen (hla) haplotype dr2 or dr4 (dr2(+) or dr4(+)). | |||||||
Copyright 2024